Moderna's RSV Vaccine Now Available for Younger Adults at Higher Risk – FDA Expands Approval
2025-06-13
ABC News
In a significant move to combat respiratory syncytial virus (RSV), the U.S. Food and Drug Administration (FDA) has broadened its approval of Moderna's RSV vaccine, Arexvy. Initially authorized for adults aged 60 and older, the expansion now extends ...Read more